Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors

Abstract excerpt

PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers harbouring a pathogenic variant in BRCA1 or BRCA2, where PARP1 inhibition results mainly in synthetic lethality in cells with impaired homologous recombination. However, the increasingly wide use of PARP inhibitors in clinical practice has highlighted the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy
• Share to Plant Genetic and Mutation Studies